Needham analyst Mike Matson downgraded Surmodics to Hold from Buy.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRDX:
- Surmodics price target lowered to $34 from $46 at Needham
- Surmodics raises FY23 EPS view to ($2.09) to ($1.69), consensus ($2.38)
- Surmodics reports Q1 EPS (50c), consensus (66c)
- Surmodics initiates organizational changes, cuts workforce by about 13%
- Surmodics price target lowered to $61 from $70 at Barrington